Drug
Radium 223 Dichloride
Radium 223 Dichloride: highest development phase Phase 2, developed by Bayer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Bayer
Trials
| Drug | Phase | Indication |
|---|---|---|
| Radium-223 dichloride (Xofigo, BAY88-8223) NCT02258451 | Phase 2 | Breast Neoplasms |
Latest
No recent events.
Follow Radium 223 Dichloride on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.